Perez-Ruiz, Elisabeth
Minute, Luna
Otano, Itziar
Alvarez, Maite
Ochoa, Maria Carmen
Belsue, Virginia
de Andrea, Carlos
Rodriguez-Ruiz, Maria Esperanza
Perez-Gracia, Jose Luis
Marquez-Rodas, Ivan
Llacer, Casilda
Alvarez, Martina
de Luque, Vanesa
Molina, Carmen
Teijeira, Alvaro
Berraondo, Pedro
Melero, Ignacio
Article History
Received: 14 September 2018
Accepted: 27 March 2019
First Online: 1 May 2019
Competing interests
: I.M. reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, CYTOMX, Incyte, MedImmune, Tusk, F-Star, Genmab, Molecular Partners, Alligator, Bioncotech, MSD, Merck-Serono and Bayer, and research funding from Roche, BMS, Alligator and Bioncotech. P.B. reports advisory roles with Tusk and Moderna, research funding from Sanofi, Moderna and Bavarian Nordic and speaker honoraria from BMS, MSD, Novartis and AstraZeneca. I.M.-R. reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, Incyte, Merck, Amgen, Pierre Fabre, Novartis, and Bioncotech. J.L.P.-G. reports advisory roles with Roche, MSD and BMS, travel support from Roche, BMS and MSD and research funding from Roche, BMS, MSD, Ipsen, Eisai, Incyte and Janssen. E.P.-R. reports speaker honoraria and travel support from BMS, MSD and Novartis. The rest of the authors have no conflict of interest to declare.